Investigation of Psychedelic Effects in Psychoactive Substances
NCT06772753
Recruiting
The aim of this double-blind, placebo-controlled, within-subjects study is to determine whether other psychoactive substances can produce experiences akin to those seen with classic psychedelics. Screening involves a medical and psychiatric examination, including blood draw, history and physical, interviews, and questionnaires. Eligible participants will then be asked to complete up to 6 experimental drug administration session during which the participants will potentially receive and report on... Read More
Gender:
ALL
Ages:
Between 25 years and 55 years
Trial Updated:
02/05/2025
Locations: Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland
Conditions: Psychedelic Effects in Healthy Volunteers
Register for Updates
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial
NCT03367533
Completed
The proposed study will assess the combined effect of perampanel and ketamine on the anti-depressant response in individuals with treatment resistant depression. The purpose of this study is to test the hypothesis that stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid receptors (AMPAR) is critical to the anti-depressant response of ketamine.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/04/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Depressive Disorder, Major, Bipolar Disorder, Post Traumatic Stress Disorder
Register for Updates
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
NCT05915013
Recruiting
The proposed study will assess the combined effect of perampanel and ketamine on the anti-depressant response in individuals with treatment resistant depression. The purpose of this study is to test the hypothesis that stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid receptors (AMPAR) is critical to the anti-depressant response of ketamine.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
02/04/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Depressive Disorder, Major, Post Traumatic Stress Disorder
Register for Updates
A Mass Balance Study With a Microtracer Dose of 14C-esketamine in Healthy Male Participants
NCT02674295
Completed
The purpose of this study is to determine the metabolic disposition of radiolabeled esketamine administered by the oral and intravenous routes in healthy male participants.
Gender:
MALE
Ages:
Between 18 years and 55 years
Trial Updated:
01/31/2025
Locations: Not set, Madison, Wisconsin
Conditions: Healthy
Register for Updates
A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine
NCT02611505
Completed
The purpose of this study is to evaluate the pharmacokinetics, safety, and tolerability of intranasally administered esketamine in both participants with varying stages of hepatic impairment and healthy participants.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
01/31/2025
Locations: Not set, Knoxville, Tennessee
Conditions: Hepatic Impairment, Normal Hepatic Function
Register for Updates
Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly Japanese, and Healthy Younger Adult Japanese Subjects
NCT02857777
Completed
The purpose of this study is to compare the pharmacokinetics, safety, and tolerability of intranasally administered esketamine in elderly Japanese subjects and healthy younger adult Japanese subjects.
Gender:
ALL
Ages:
20 years and above
Trial Updated:
01/31/2025
Locations: Not set, Cypress, California
Conditions: Healthy
Register for Updates
Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment
NCT06069843
Active Not Recruiting
Ketamine is a NMDA-receptor antagonist that promotes synapse formation and has been shown to rapidly improve symptoms in depression. Even a single dose of ketamine has been shown to improve depression and cognition with short-term memory, inhibitory control, cognitive flexibility, and processing speed showing improvements within days of treatment. The mechanism behind ketamine's rapid action is not clear but some groups have speculated it may be related to enhanced neuroplasticity, particularly... Read More
Gender:
ALL
Ages:
Between 50 years and 90 years
Trial Updated:
01/27/2025
Locations: Icahn School of Medicine at Mount Sinai (Depression and Anxiety Center), New York, New York
Conditions: Depression, Mild Cognitive Impairment
Register for Updates
Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression
NCT06559826
Recruiting
The proposed study is a single-site, randomized, controlled clinical trial (RCT) comparing ketamine-assisted psychotherapy (KAP) to a standard evidence-based regimen of ketamine administered in a medical model without psychotherapy (KET). Eligible study participants will be adults with major depressive disorder (MDD). Adults with MDD will be randomized to KAP or KET in a 1:1 allocation. Each treatment group will receive KAP or KET over a period of four weeks. Measurement of depression severity,... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
01/22/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Major Depressive Disorder
Register for Updates
Anesthetics and Analgesics in Children
NCT03427736
Recruiting
The purpose of this study is to characterize the pharmacokinetic (PK) and safety profile of anesthetics and analgesics in children and adolescents.
Gender:
ALL
Ages:
Between 0 years and 17 years
Trial Updated:
01/21/2025
Locations: Lucile Packard Children's Hospital, Stanford, California +12 locations
Conditions: Anesthesia, Pain
Register for Updates
Ketamine Vs Lidocaine in Traumatic Rib Fractures
NCT04781673
Recruiting
Rib fractures continue to be a common occurrence in trauma patients of all ages. Traumatic rib fractures can cause severe pain in patients and lead to shallow breathing and further complications such as the need for mechanical ventilation, hospital or ventilator associated pneumonia, atelectasis, and acute respiratory distress syndrome. Effective multimodal pain management is needed to optimize a patient's respiratory status and can also play a role in early mobility, less pulmonary complication... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2025
Locations: Spectrum Health Hospital, Grand Rapids, Michigan
Conditions: Rib Fractures, Rib Fracture Multiple, Rib Trauma
Register for Updates
The Perinatal Synergistic Multi-component Intervention to alLeviate dEpressive Symptoms. A Case Series
NCT06048263
Not Yet Recruiting
The goal of this open label case series is to learn about the feasibility of conducting a future randomised controlled trial to evaluate how well the Perinatal SMILES intervention works in improving post-cesarean mood in low-income women. The main questions it aims to answer are: 1. Is it feasible to recruit a sufficient number of participants? 2. Is it feasible to administer Perinatal SMILES and 3. Is it feasible to collect participant outcomes? To profile EEG in participants at rest and in... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
01/14/2025
Locations: Barnes-Jewish Hospital, Saint Louis, Missouri
Conditions: Postpartum Depression
Register for Updates
The Impact of Perioperative Ketamine Infusion on Surgical Recovery
NCT04625283
Completed
In order to effectively treat surgical pain with the least amount of opioids required, a multi-modal approach must include medications with different mechanisms of actions at alternative receptors. In light of the opioid epidemic, medical providers at Vanderbilt University Medical Center (VUMC) are strategically combining these medications in a bundled pain-regimen after surgery. These regimens have been shown to decrease opioid consumption, improve surgical outcomes, and reduce hospital stays,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/10/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Opioid Use, Enhanced Recovery After Surgery, Anesthesia, Ketamine, Pain, Postoperative
Register for Updates